Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Science.
Press releases published on May 28, 2025
Kraig Biocraft Laboratories Announces New Spider Silk Parental Strain for Expanded Commercial Production
GlobeNewswire
·
May 28, 2025
ANN ARBOR, Mich., May 28, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces today the successful development of a new recombinant spider silk parental …
Tokenize! Global Wraps Up Bitcoin Week with Leading Investor Summit
GlobeNewswire
·
May 28, 2025
LAS VEGAS, NV, May 28, 2025 (GLOBE NEWSWIRE) -- (aka Bitcoin Pizza Day) – Tokenize! will hold its second annual Global Summit in Las Vegas on May 29-31, at an extravagant 18,000 square foot celebrity mansion on a two-acre, gated estate in Las Vegas’ most …
Avacta Therapeutics Announces Appointments of Industry Veterans to Board of Directors
GlobeNewswire
·
May 28, 2025
LONDON and PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces the …
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 28, 2025
WALTHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with …
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting
GlobeNewswire
·
May 28, 2025
90 mg once-daily palazestrant dose selected for Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with ribociclib OPERA-01 trial-in-progress poster to be presented on Monday, June 2 between 9:00am–12:00pm CT / …
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025
GlobeNewswire
·
May 28, 2025
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that its management team is scheduled …
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
GlobeNewswire
·
May 28, 2025
– Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 – BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, …
NASA Visits Constellium Ravenswood to Celebrate Artemis Partnership
GlobeNewswire
·
May 28, 2025
PARIS, May 28, 2025 (GLOBE NEWSWIRE) -- Constellium SE (NYSE: CSTM) is honored to welcome NASA representatives to its Ravenswood, West Virginia facility today to celebrate their collaboration on the Artemis program — NASA’s bold mission to return humans to …
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 28, 2025
SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today …
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 28, 2025
BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer …
Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 28, 2025
SAN FRANCISCO, May 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that …
Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration
GlobeNewswire
·
May 28, 2025
Enrollment for SOL-R, the largest retinal TKI trial to date, supports randomization of at least 555 subjects SOL-1, Ocular’s first registrational trial in wet AMD, completed randomization in December 2024 and retention remains exceptional as the trial …
BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
GlobeNewswire
·
May 28, 2025
FLORHAM PARK, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster …
BPGbio Presents Advances in Spatial Omics Technology and Targeted Protein Degradation Insights at ASMS 2025
GlobeNewswire
·
May 28, 2025
BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered clinical-stage biopharma company, today announced that the company will present groundbreaking research across five sessions at the 72nd American Society for Mass …
Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split
GlobeNewswire
·
May 28, 2025
SARASOTA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company advancing innovative treatments for brain-related health conditions, today announced that its Board of Directors (the “ …
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
GlobeNewswire
·
May 28, 2025
If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually in the US1 with many cases requiring hospitalization, …
Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference
GlobeNewswire
·
May 28, 2025
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and …
Velocity comes out of stealth with $10M to power the Velocity of Money
GlobeNewswire
·
May 28, 2025
London, May 28, 2025 (GLOBE NEWSWIRE) -- Velocity announces a $10M pre-seed funding round and emerges from stealth to launch the Stablecoin Payment Account. The round was led by Activant Capital, with participation from Fuel Ventures, Triton Capital, …
Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline
GlobeNewswire
·
May 28, 2025
Company’s Part A data readout from first-in-human Phase 1 Trial 1001 in patients with recurrent or refractory metastatic solid tumors known to express GD2, validates GD2-SADA as safe, tolerable and able to achieve targeted in vivo conjugation of 177Lu-DOTA …
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
GlobeNewswire
·
May 28, 2025
--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial efficacy and safety data, enobosarm 3mg will advance as …